Multicentre, randomised, double-blind, parallel-group, Phase III study to evaluate the genetic polymorphisms influence in the response to Ranibizumab and Bevacizumab treatment in patients with Age-Associated Macular Degeneration

Status

Not yet recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-518990-33-00

Enrollment

574

Registered

2024-10-25

Start date

Unknown

Completion date

Unknown

Last updated

2025-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Age-Associated Macular Degeneration

Brief summary

Visual acuity score measured on ETDRS at 4 meters of initial distance or Snellen with conversion to ETDRS if necessary, using the method proposed by Rosenfeld et al, between the baseline and final evaluations. Main outcome will be assessed at 1 year.Genetic polymorphism: Saliva samples will be collected using oral swabs suitable for obtaining DNA. The genomic DNA will be obtained from a first digestion of the sample wit

Interventions

DRUGAvastin 25 mg/ml concentrate for solution for infusion.

DRUGRANIBIZUMAB

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Visual acuity score measured on ETDRS at 4 meters of initial distance or Snellen with conversion to ETDRS if necessary, using the method proposed by Rosenfeld et al, between the baseline and final evaluations. Main outcome will be assessed at 1 year.Genetic polymorphism: Saliva samples will be collected using oral swabs suitable for obtaining DNA. The genomic DNA will be obtained from a first digestion of the sample wit	—

Measure

Time frame

—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026